The FDA issues rigorous new accuracy standards for in vitro diagnostic tests, including for #alzheimersdisease . ow.ly/z4Be50RCimC

Large study makes the case for redefining APOE4 homozygosity as a genetically determinant form of AD. Some scientists disagree. Institut de Recerca Sant Pau ow.ly/jQxw50RC3mC

The #alzheimersdisease risk gene PLCγ2 acts in neurons as well as microglia, maintaining synapse number and excitability. Institut Pasteur de Lille ow.ly/NnqW50RASxy

Locus coeruleus degeneration on MRI, a proxy for tau tangles, precedes tau PET positivity in the medial temporal lobe and poor cognition three years later. MassGeneral News Harvard Medical School ow.ly/O4FW50RAJHh

The endosomal receptor SORL1, known for shuttling APP, also binds to and co-localizes with tau in cells. Knocking down SORL1 reduced tau seeding; the N1358S risk variant ramped it up. Mass General Brigham University of Maryland School of Medicine ow.ly/5jGJ50Rwx1z

From treadmills to transcriptomes: body-wide omics studies chart the molecular response to endurance training in rats. ow.ly/iXKZ50RwlHZ

In the DIAN prevention trial, plaque-clearing antibody gantenerumab improved fluid biomarkers of neuroinflammation and synaptic function. #alzheimersdisease @wustl ow.ly/nIB750Rw5nw

Tauopathy neurons make more lipids than they break down, forcing them to export the fat to microglia, triggering neuroinflammatory responses. A dearth of neuronal AMP kinase exacerbates the process. UC San Diego ow.ly/c3Sm50Rt1SU

Without γ-secretase, APP C-terminal fragments accumulate in lysosomes, blocking influx of calcium from the endoplasmic reticulum. KU Leuven ow.ly/i4Za50RpWa9

In amyloidosis mice, some TREM2-positive microglia become senescent and harm the brain. #alzheimersdisease Weizmann Institute ow.ly/uQNS50RpJW9

In neurons, lysosomes transport certain mRNAs into axons, maintaining ribosomal and mitochondrial function in these synaptic hot spots. NIH ow.ly/pYHW50RpocO

The GLP-1 analogue lixisenatide helped Parkinson’s patients in a small Phase 2 trial maintain their motor abilities over one year. #parkinsonsdisease Université de Toulouse ow.ly/aCPk50Rocae

A new p-Tau212 assay shows promise as a plasma biomarker of #alzheimersdisease , rivaling the performance of p-Tau217. Göteborgs universitet / University of Gothenburg ow.ly/kWKk50RktPT

Peptides possess the power to spark propagation of tau fibrils, or to dismantle fibrils entirely. Two studies point to therapeutic strategies for tauopathies. UC Santa Barbara @ucla ow.ly/fGY750RkjcX

At #ADPD , scientists showcased preclinical efforts to target microglia in AD, by activating TREM2, blocking CD33, and stopping ASC specks. AD/PD - Advances in Science & Therapy ow.ly/EnVX50Rk9t3

At #ADPD , scientists parsed microglial and astrocytic contributions to AD pathophysiology. Microglia change their tune as disease worsens. AD/PD - Advances in Science & Therapy ow.ly/3rh850RftJN

Sumoylation influences tau phosphorylation and aggregation, with SUMO1 promoting, and SUMO2 preventing, these processes. #alzheimersdisease AD/PD - Advances in Science & Therapy Columbia University Istituto Mario Negri University of Toronto ow.ly/87NR50Rfh1v

Microglia expressing the inhibitory receptor LILRB4 laze around plaques in #Alzheimersdisease and amyloidosis mice. An antibody against LILRB4 stirred microglia to engulf Aβ fibrils and lower plaque load. Washington University in St. Louis ow.ly/7zvU50RexJh

A p-tau217 antibody reduced tangles and neurodegeneration and improved memory and coordination in mice. It, and another antibody targeting N-terminal tau, restored brain proteostasis to wild-type levels. Xiamen University UQ News ow.ly/1CGt50Remw7

Researchers at AD/PD 2024 discussed progress in developing disease-modifying therapies for synucleinopathies. #parkinsonsdisease AD/PD - Advances in Science & Therapy ow.ly/sPMC50RcMUi